Why my portfolio of small-cap calls is printing, and why I’m not selling yet (KEEL, PLUG, ACHR, RXRX)
​
Alright you beautiful degenerates, look at this screenshot before you call me a lucky idiot. Yes, the numbers are blacked out because my wife’s boyfriend doesn't need to know exactly how much cash I’m working with, but the percentages don't lie. I’m sitting on a heap of deep-in-the-money and highly green options contracts, mostly riding on KEEL (Keel Infrastructure), with some speculative fuel on the side.
Here is the DD on why this portfolio isn't just a fluke, but a calculated bet on the next leg of tech, energy, and infrastructure macro trends.
1. The KEEL Moat: AI & Digital Infrastructure Is the New Oil
If you aren't paying attention to Keel Infrastructure Corp, you are missing the literal foundation of the AI boom. Look at my strikes: $2, $2.50, $3, $5. With the stock currently trading around $4.39, a massive chunk of my position is heavily in-the-money, and the percentage gains reflect it (+136%, +327%, +305%).
The Thesis: AI needs data centers, and data centers need absolute metric tons of electricity. KEEL has a 2.2 gigawatt pipeline with secured grid interconnections across key power markets (Pennsylvania, Washington, Québec).
The Play: They just reported Q1 earnings earlier this month. Wall Street is finally realizing that the bottleneck for tech isn’t software; it’s physical infrastructure and power capacity. Seven analyst buy ratings against one hold. I’m riding these calls because the infrastructure squeeze is just getting started.
2. PLUG $5 Call: Playing the Operational Turnaround
PLUG has been a battleground stock for years, but look at the recent price action—it’s climbed back to around $3.78, giving my $5 calls a gorgeous +71.57% lift on the back of rising implied volatility and momentum.
The Thesis: Love it or hate it, Plug Power is pushing hard toward operating profitability this year. The momentum in electrolyzer sales is finally catching a bid. As the macro environment stabilizes, any positive surprise on their margins sends this thing flying. It's a high-beta runner, and the option leverage is working exactly like it’s supposed to.
3. ACHR $10 Call: eVTOL Flying Taxi Hype
Archer Aviation is sitting at $6.05, and while $10 is out-of-the-money, the market is mispricing the massive upside potential here. The Street has a consensus price target averaging double the current price, with some analysts shouting for $18.
The Thesis: We are approaching the commercialization phase of eVTOL (electric vertical takeoff and landing) aircraft. Archer has massive institutional backing and partnerships. This is a pure asymmetric risk/reward play. If they clear the next regulatory hurdle, the gamma squeeze on the $10 strikes will be violent.
4. RXRX $5 Call: The Dip I’m Buying
Yes, Recursion Pharmaceuticals is the lone red eye sore in my portfolio right now at -22.41%. But look at the strike: $5.
The Thesis: RXRX is an AI-driven drug discovery play. Biotechs are volatile by nature, but their tech stack and data partnerships are elite. At a $5 strike, this is an incredibly cheap entry for a company that can double overnight on a single successful phase trial or data readout. It balances out the pure infrastructure plays with high-upside biotech lottery tickets.
TL;DR / Conclusion
This isn't a random collection of meme stocks. It’s a hyper-focused bet on the physical limits of the tech boom (data centers, clean energy grids, next-gen transport, and AI biotech). The KEEL calls are providing a massive baseline of ITM profit, allowing me to let the higher-beta plays like PLUG and ACHR run.
Positions are in the screenshot. Tell me why I'm a genius or why I'll be working back at Wendy's by next Friday.